LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services
Starting January 1, 2026, hospitals providing these Medicare-covered therapies for epilepsy will benefit from higher reimbursement rates, potentially...
Read Full Article →